The present study unveils a previously unidentified epigenetic pathway in AKI, whereby lactate-driven H3K18 lactylation transcriptionally activates HSPA6, consequently promoting cuproptosis and exacerbating renal damage. The "lactate-H3K18la-HSPA6" axis has been identified as a promising new target for therapeutic intervention in AKI.
Sui et al. (Thu,) studied this question.